Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3CQV6)

Drug Name
DIASTEREOMER 2 Drug Info
Synonyms
571170-81-5; 2-(4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; DIASTEREOMER 2; CHEMBL221007; 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-Cyclopent[b]indole-3-acetic acid; MK-0524 Laropiprant; SCHEMBL1044552; CTK8C2002; DTXSID00436805; CS-M1273; KS-00001EH0; ANW-67605; BDBM50205278; AKOS016006816; KB-71920; CS-13849; AX8238513; TC-156350; 126596-EP2295409A1; 1-(4-Chlorobenzyl)-5-fluoro-7-mesyl-2,3-propano-1H-indole-10-ylacetic acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10216733
CAS Number
CAS 571170-81-5
TTD Drug ID
DM3CQV6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Prostaglandin D2 receptor (PTGDR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [1]
Setipiprant DMZ61IA Asthma CA23 Phase 3 [2]
QAW-039 DMPCFXN Asthma CA23 Phase 3 [3]
AMG 853 DM973N4 Asthma CA23 Phase 2 [4]
ONO-4053 DMX4MVP Allergic rhinitis CA08.0 Phase 2 [5]
TS-022 DMMNXIW Atopic dermatitis EA80 Phase 2 [6]
S-555739 DMXDVNZ Allergy 4A80-4A85 Phase 2 [7]
MK-1029 DM8ZTW7 Asthma CA23 Phase 2 [8]
SAR-389644 DMA6O9R Allergic rhinitis CA08.0 Phase 1 [9]
192C86 DMQ8NTZ Thrombosis DB61-GB90 Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin D2 receptor (PTGDR) TTNVEIR PD2R_HUMAN Inhibitor [1]

References

1 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Effect Of QAW039, An Oral Prostaglandin D2 Receptor (DP2/CRTh2) Antagonist, Upon Sputum And Bronchial Eosinophilic Inflammation And Clinical Outcomes In Treatment-Resistant Asthma: A Phase 2a Randomized Placebo-Controlled Trial. American Thoracic Society Journals. 2015.
4 Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45.
5 Effect of ONO-4053, a DP1 (prostaglandin D2 receptor) Antagonist, on Prostaglandin D2-Induced Nasal Congestion. Journal of Allergy and Clinical Immunology Volume 135, Issue 2, Supplement, February 2015, Pages AB219.
6 Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis... Eur J Pharmacol. 2007 Feb 5;556(1-3):207-14.
7 Clinical pipeline report, company report or official report of Shionogi (2011).
8 Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66.
9 US patent application no. 2008,0300,217, Combination therapy with fumaric acid esters for the treatment of autoimmune and,or inflammatory disorders.
10 Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol. 2009 September; 158(1): 104-145.